- Previous Close
2.5000 - Open
2.5100 - Bid 2.5700 x --
- Ask 2.6400 x --
- Day's Range
2.5000 - 2.5900 - 52 Week Range
1.4400 - 3.1600 - Volume
6,900 - Avg. Volume
22,980 - Market Cap (intraday)
63.521M - Beta (5Y Monthly) 1.96
- PE Ratio (TTM)
43.17 - EPS (TTM)
0.0600 - Earnings Date Aug 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.31
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.
www.medexus.com82
Full Time Employees
March 31
Fiscal Year Ends
Healthcare
Sector
Drug Manufacturers - Specialty & Generic
Industry
Recent News: MDP.TO
View More
Performance Overview: MDP.TO
Trailing total returns as of 2024-10-24, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDP.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDP.TO
View MoreValuation Measures
Market Cap
63.52M
Enterprise Value
116.63M
Trailing P/E
46.86
Forward P/E
15.75
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.41
Price/Book (mrq)
1.41
Enterprise Value/Revenue
0.77
Enterprise Value/EBITDA
4.67
Financial Highlights
Profitability and Income Statement
Profit Margin
1.00%
Return on Assets (ttm)
4.89%
Return on Equity (ttm)
3.95%
Revenue (ttm)
108.78M
Net Income Avi to Common (ttm)
1.09M
Diluted EPS (ttm)
0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
8.45M
Total Debt/Equity (mrq)
143.72%
Levered Free Cash Flow (ttm)
13.51M